Compass Therapeutics, Inc. — Director's Dealing 2021

May 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Compass Therapeutics, Inc. (NONE)
CIK: 0001738021
Period of Report: 2021-05-03

Reporting Person: Kalled Susan (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-03	Stock Option (Right to Buy)	$7.00	A	260000	Acquired	2031-05-03	Common Stock (260000)	Direct

Footnotes

F1: 25% of this option vests on May 3, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.